4SC AG (FSCGF.PK), a biotech firm focused on discovery and development, Tuesday said its first quarter loss narrowed, backed on by higher revenues. The firm attributed the revenue increase mainly to the cooperation agreements signed with BioNTech AG and LEO Pharman A/S.
For the first quarter, the firm reported loss of 2.6 million euros, compared with the loss of 3.6 million euros during the corresponding quarter last year. On a per share basis, the loss for the quarter was euro 0.05 per share compared with loss of euro 0.09 per share last year. The company said there has been no tax for the period.
Revenues for the three-month period rose up to 0.79 million euros, from the prior year's figure of 0.36 million euros.
For comments and feedback: editorial@rttnews.com